Hologic's GYN Surgical Delivers a Standout Quarter: What's Behind It?
HOLX's GYN Surgical segment posts its strongest fiscal 2025 growth as MyoSure, Fluent and Gynesonics fuel a standout quarter.
Should You Continue to Hold Hologic Stock Post Q4 Earnings?
HOLX's solid Q4 growth and a pending $18.3B buyout sharpen its focus as the company prepares to end its publicly traded chapter.
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic Expands European Reach of Genius Digital Diagnostics System
HOLX gains expanded CE marking for its Genius Digital Diagnostics System, enabling imaging of both cell and tissue specimens on one platform.
Here's Why Hologic (HOLX) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Hologic (HOLX) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Hologic's Breast Health Rebounds, Takes Spotlight in Buyout Deal
After a strong Q4 rebound, HOLX's Breast Health takes center stage in the company's upcoming private equity takeover.
HOLX Stock Up on Q4 Earnings & Revenue Beat, Operating Margin Expands
Hologic posts solid Q4 gains with earnings and revenue beat, margin expansion, and a buyout deal by Blackstone and TPG.
Hologic (HOLX) Q4 Earnings and Revenues Beat Estimates
Hologic (HOLX) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $1.01 per share a year ago.
Hologic (HOLX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Hologic (HOLX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
HOLX vs. ABT: Which Medical Technology Stock Is the Better Investment?
Hologic's $18.3B buyout deal and Abbott's strong growth across key segments set up a close contest for MedTech investors.
Gear Up for Hologic (HOLX) Q4 Earnings: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Hologic (HOLX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
